Cohort Name |
TRACK HD |
Cohort Acronym |
TRACK HD |
DOI |
Tabrizi, S. (2017). TRACK HD [Data set]. Dementias Platform UK. https://doi.org/10.48532/045000 |
Study Overview |
TRACK HD is a prospective observational biomarker study in participants with premanifest and early Huntington's disease (HD). Track HD assessed longitudinal data collected at baseline, 12 months, 24 and 36 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. |
#Subjects at Baseline |
123 controls, 120 premanifest gene carriers, and 123 early HD (Stage 1 or Stage 2). |
Institution Name |
University College London |
Department Name |
UCL Institute of Neurology |
City |
London |
Study/Database Website |
http://hdresearch.ucl.ac.uk/completed-studies/track-hd/ |
Principal Investigator (PI) |
Prof Sarah Tabrizi |
Key Study References |
Please see Literature section |
Population Based Study? |
No |
Family Based Study? |
Yes |
Clinical based sample? |
Yes |
Is there follow-up data available? |
Yes |
Were participants included prior to development of dementia (may refer to controls only)? |
Yes |
Were participants included prior to development of MCI (may refer to controls only)? |
Yes |
How is data collected? |
In person |
Who carries out data collection? |
Interviewers and Clinicans |
Does this take place in participants' homes or at a central location? |
Central |
Do participants take part individually or are families/partners involved? |
Individually: Control participants were purposefully selected if they were gene negative or partners of people with HD. |
Dementia cases ascertained as part of study: |
Yes |
Diagnosis based on review of existing clinical data |
No |
Was diagnosis/primary outcomes made blind to exposure variables? |
No |
How many times followed up? |
3 |
Study start date |
01/01/2008 00:00:00 |
Study end date |
31/12/2011 00:00:00 |
Is study ongoing? |
No |
Is study still recruiting? |
No |
Inclusion criteria |
Premanifest gene carriers required a burden of pathology score greater than 250, on the basis of their medical records at the time of recruitment, and a total motor score of 5 or less in the motor assessment of the United Huntington's Disease Rating Scale (UHDRS), indicating no substantial motor signs.
Aged between 18 and 65 years, ability to tolerate MRI and biosample collection.
CAG repeat length more or equal to 40.
HD groups had to have a total functional capacity of greater than 6 from the UHDRS.
Controls were age-matched and gender-matched to individuals in the combined preHD and HD groups. |
Exclusion criteria |
Absence of major psychiatric disorder or history of significant head injury at time of enrolment.
Concomitant significant neurological disorder.
Significant medical illness.
MRI contraindications.
Predictable non-compliance.
Any significant hand injuries.
Taking part in any concurrent clinical trials. |